Ian W. Flinn, MD, PhD
At the 2018 ASCO Annual Meeting, data for the combinations of the anti-CD47 antibody Hu5F9-G4 (5F9) with rituximab (Rituxan), and ibrutinib (Imbruvica) plus venetoclax (Venclexta), both showed practice-changing potential to transform the complex field of non-Hodgkin lymphoma (NHL).
The combination of 5F9 with rituximab demonstrated strong signals of activity and tolerability in patients with relapsed/refractory NHL. The initial phase Ib/II results revealed the efficacy of 5F9 in patients with rituximab-refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.1
Across all doses, the overall response rate (ORR) was 50%, with a complete remission (CR) rate of 36%.
... to read the full story